NCT06138990

Pharmacoscopy-guided Clinical Standard-of-care in r/r AML

Pharmacoscopy-guided Clinical Standard-of-care in Relapsed/Refractory Acute Myeloid Leukemia, a Randomized Phase-2 Clinical Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 88 (estimated)
• Sponsor: ETH Zurich · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed/refractory AML.

Conditions

• AML, Adult

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Pharmacoscopy	Pharmacoscopy (PCY) is an image-based ex vivo drug testing platform developed by the Snijder lab at the ETH Zurich. PCY measures in the drug response of patient cells from small biopsies using automated microscopy and single-cell image analysis. PCY prioritizes treatments based on their specific efficacy against AML cells, while minimizing toxicity to healthy (non-malignant) cells in the patient biopsy.
DRUG	Clinical standard-of-care (physician's choice)	Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).

Timeline

• Start date: 2024-09-02
• Primary completion: 2026-06-30
• Completion: 2026-06-30
• First posted: 2023-11-18
• Last updated: 2025-05-16

Locations

2 sites across 1 country: Switzerland